Biocause Pharma(SZ:000627) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-08-26 04:20Core Viewpoint - *ST Tianmao has made significant progress towards voluntary delisting, with shareholders approving the proposal to terminate the company's stock listing with a 98.06% agreement rate at the extraordinary general meeting held on August 25 [1][2]. Group 1: Delisting Process - The company will submit an application to the Shenzhen Stock Exchange for the termination of its stock listing within fifteen trading days after the shareholders' resolution [2]. - The last trading day for *ST Tianmao was August 13, with a closing price of 1.58 yuan [3]. - Shareholders eligible for cash options can exercise their rights at a price of 1.60 yuan per share during the cash option declaration period [3]. Group 2: Financial Implications - The cash option will be distributed based on the number of shares held by eligible shareholders as of the cash option registration date on September 2, 2025 [3]. - Jingmen Weituo Hongcheng Management Partnership (Limited Partnership) is expected to provide cash options for up to 1.629 billion shares, with the final distribution quantity to be confirmed after the registration date [3]. Group 3: Regulatory Issues - The company faces a risk of forced delisting due to the failure to disclose the 2024 annual report and the 2025 first-quarter report within the legal timeframe [4]. - The company has been under investigation by the China Securities Regulatory Commission for failing to disclose periodic reports on time [4]. Group 4: Industry Trends - Several companies have opted for voluntary delisting this year, indicating a trend towards companies choosing to exit the market proactively [5][6]. - The increasing number of voluntary delistings reflects a maturing market mechanism, with the concept of "voluntary exit" becoming more accepted among companies [7].